AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01162135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: The participants will take study drug digoxin, which is approved by FDA for the treatment of CHF, 125 or 250 mcg orally daily, titrated to the level of 0.8 - 2 ng/ml for total of 6 cycles (4 weeks/cycle). The lower dose of digoxin (such as 125 mcg/day) will be chosen if serum level reaches 0.8 ng/ml already. Patients may continue another 6 cycles if evident of clinical benefit.~It is possible that some patients may need to receive 500 mcg per day to reach this targeted drug level. No further titration will be allowed beyond this FDA approved digoxin dose.
Study NCT04794452 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Battery operated toothbrush
Description: Device on plaque removal efficacy
Study NCT04794452 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual toothbrush
Description: Device on plaque removal efficacy
Study NCT02420665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine
Description: 0.01% Proflavine applied topically to the cervix after colposcopy and HRME cervical images obtained.
Study NCT02420665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HRME Imaging
Description: HRME images obtained from one visually normal cervical site, and from up to 3 visually abnormal lesions based on exam and/or colposcopic findings.
Study NCT02420665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Study staff follow up with participant by phone one month after procedure.
Study NCT02420665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: Colposcopy performed after visual inspection of cervix.
Study NCT02420665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetic Acid
Description: 3 - 5% added to cervix before visual inspection.
Study NCT00022126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Study NCT00022126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00022126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00022126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00022126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Study NCT00022126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00022126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00022126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Study NCT00022126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00022126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Study NCT00022126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Study NCT00022126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Study NCT00022126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00022126 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Study NCT00022126 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT03851107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement in 6-week community-based activity program
Description: Participants engage in a 6-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 6 weeks - the actual intervention phase.
Study NCT01968837 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Cervical cancer screening
Study NCT03576131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN1029 (HexaBody®-DR5/DR5)
Description: GEN1029 will be administered intravenously. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
Study NCT04259879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Food intake restriction
Study NCT02593084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Higher Intensity Resistance Training
Description: Bi-weekly resistance training for 12 weeks using multi-joint movements involving both upper and lower extremities (e.g squats). Participants will perform 3-5 sets of 3-6 repetitions at Rating of Perceived Exertion 8/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
Study NCT02593084 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lower Intensity Resistance Training
Description: Bi-weekly resistance training for 12 weeks using single-joint movements involving both upper and lower extremities (e.g leg extension). Participants will perform 3-5 sets of 8-10 repetitions at Rating of Perceived Exertion 5/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
Study NCT02729025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered subcutaneously once a month using an autoinjector/pen.
Study NCT02729025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously once a month using an autoinjector/pen.
Study NCT01747239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 25 mg/m2 IV every three weeks
Study NCT01046721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: single dose of 5 microg Exenatide. Subcutaneous administration
Study NCT01046721 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: subcutaneous administration of 0.9% saline solution (0.02 ml)
Study NCT04430101 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally invasive stabilization of Lisfranc injuries
Description: Patients with positive weightbearing radiographs will be operated by minimally invasive stabilization (eg, isolated homerun screw)
Study NCT04430101 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Patients with negative weightbearing radiographs will be treated conservatively
Study NCT02364219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prewarming
Description: Patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
Study NCT02364219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdialysis
Description: 71 High Cut-Off Brain MD Catheter Membrane cut-off: 100 kDa Membrane length 30 mm Shaft length: 60 mm Dialysis AB, Stockholm, Sweden
Study NCT03940027 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-guided celiac plexus neurolysis
Description: EUS-guided celiac plexus neurolysis (EUE-CPN) is an endoscopic ultrasound-guided injection of local anesthetics and neurodegenerative agents into the abdominal ganglion area through the gastric wall, so as to achieve irreversible damage of the abdominal nerve and interrupt the pain pathway of pancreatic cancer.EUS-CPN has the advantages of less trauma, higher technical success rate and lower risk of complications compared with traditional ct-guided CPN in vitro puncture.The data showed that eus-cpn was effective in the treatment of pancreatic cancer related persistent abdominal pain up to about 70%, significantly reducing the dosage of analgesics and improving the quality of life of patients with advanced pancreatic cancer.
Study NCT03940027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-guided celiac plexus neurolysis
Description: EUS-guided celiac plexus neurolysis (EUE-CPN) is an endoscopic ultrasound-guided injection of local anesthetics and neurodegenerative agents into the abdominal ganglion area through the gastric wall, so as to achieve irreversible damage of the abdominal nerve and interrupt the pain pathway of pancreatic cancer.EUS-CPN has the advantages of less trauma, higher technical success rate and lower risk of complications compared with traditional ct-guided CPN in vitro puncture.The data showed that eus-cpn was effective in the treatment of pancreatic cancer related persistent abdominal pain up to about 70%, significantly reducing the dosage of analgesics and improving the quality of life of patients with advanced pancreatic cancer.
Study NCT04529499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVIGAN
Description: Patients will be randomized to the favipiravir + supportive care group in a 1:1 ratio
Study NCT04529499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Patients will be randomized to the placebo + supportive care group in a 1:1 ratio
Study NCT01154400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein protein hydrolysates
Description: 15 g casein protein hydrolysates + 15 g maltodextrin
Study NCT01154400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysates
Description: 15 g whey protein isolate + 15 g maltodextrin
Study NCT01154400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein protein hydrolysates + LEU
Description: 15 g casein protein hydrolysate + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
Study NCT01154400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysates + LEU
Description: 15 g whey protein isolate + 1.5 g LEU (40% of EAA content) + 15 g maltodextrion
Study NCT00861731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvasatin therapy alone at the dose of 40 mg/day
Study NCT01514981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 761
Description: Single dose of AMG 761 on study day 1.
Study NCT01514981 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo on study day 1.
Study NCT03101631 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA)
Description: CGA includes a set of evaluations to determine therapeutic decision based on mortality risk, toxicity risk and frailty group. Evaluations includes:~* Nutritional Assessment: Mini Nutritional Assessment (MNA)~* Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.~* Cognitive Assessment: Mini-Mental State Examination (MMSE-30)~* Psychological status: Geriatric Depression Scale (GDS)~* Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)~* Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)~* Age~* Haemoglobin~* CrCl~* Presence of geriatric syndromes
Study NCT04593485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab for injection
Description: Carrelizumab will be administered at a fixed dose
Study NCT04209452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehearsal strategy
Description: Teaching children to cumulatively rehearse numbers as they are being said.
Study NCT04209452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforcement
Description: Providing reinforcement for correct recall after a delay.
Study NCT00861731 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: EZE/simvastatin
Description: EZE/simvastatin combined therapy at the dose of 10/20 mg/day
Study NCT00861731 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: EZE/simvastatin
Description: EZE/simvastatin combined therapy at the dose of 10/40 mg/day
Study NCT04488731 — intervention group
Intervention type: BEHAVIORAL
Intervention: Normal BMI and heavy coffee consumption
Description: Normal BMI and heavy coffee consumption
Study NCT04488731 — intervention group
Intervention type: BEHAVIORAL
Intervention: overweight and moderate coffee consumption
Description: overweight and moderate coffee consumption
Study NCT04209452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehearsal strategy and reinforcement
Description: Teaching children to cumulatively rehearse numbers as they are being said, AND providing reinforcement for correct recall after a delay.
Study NCT03751033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BSS
Description: Intraoperative aberrometry measurements for BSS will be performed.
Study NCT03751033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiscoVisc
Description: Intraoperative aberrometry measurements for DiscoVisc will be performed.
Study NCT04025060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commercially-available caffeine-free soda
Description: Subjects are asked to consume caffeine-free soda daily for two weeks
Study NCT04025060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Carbonated water
Description: Subjects are asked to consume unsweetened, carbonated water daily for two weeks
Study NCT04025060 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular soda
Description: Subjects are asked to consume regular soda daily for two weeks
Study NCT04468022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Toric Trifocal IOL
Description: Interventions are performed using a standard technique of sutureless phacoemulsification. In all cases, topical anesthesia was administered and pharmacologic mydriasis was induced using a combination of tropicamide and phenylephrine (10.0%). A mean clear corneal microincision of 2.2 mm was made with a knife according to position of the preop highest K value of the patient. A paracentesis was made 60 degree to 80 degree, clockwise from the main incision, and the anterior chamber was filled with an ophthalmic viscoelastic (OVD) after phacoemulsification/lensectomy and removal of clear lens. The IOL was subsequently implanted through the main incision using the BLUEMIXS 180 injector (Carl Zeiss meditec, Jena, Germany) for trifocal IOL , VISCOJECTTM BIO injector for toric trifocal IOL and then the OVD was removed. Postoperative pharmacologic treatment is performed with the combination of antibiotic and steroidal anti-inflammatory drops
Study NCT04488731 — intervention group
Intervention type: BEHAVIORAL
Intervention: overweight and heavy coffee consumption
Description: overweight and heavy coffee consumption
Study NCT02647008 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.These small battery powered devices deliver alternating current via cutaneous electrodes positioned near the painful area.
Study NCT02647008 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS
Description: Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.These small battery powered devices deliver alternating current via cutaneous electrodes positioned near the painful area.
Study NCT02685228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: decitabine 5mg/m2,d1-d5;
Study NCT02685228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1.0g/m2, d8,d15,d22
Study NCT02685228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: gemcitabine 1.0g/m2, d8,d15,d22
Study NCT02261272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for insomnia SHUTi
Description: SHUTi
Study NCT03422081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: arterial doppler ultrasound
Description: doppler ultrasound
Study NCT01472315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medroxyprogesterone acetate
Description: MPA hormone therapy 30mg two hours before bedtime and 30mg right before going to bed every night for two weeks period
Study NCT01472315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills were taken in same way as active comparator
Study NCT02111382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CV4 Cranial (4th ventricle technique) Osteopathic Manipulative
Description: The participant will be in supine position during the whole procedure. The practitioner sits behind the participant's head, contacts participant's lateral protuberances of the squama occipitalis (medially to the occipitomastoid suture) with the thenar eminence of both hands.~When the practitioner feels the PRM (a pulsating rhythm caused by liquor production and reabsorption), the flexion phase will be resisted and the extension phase exaggerated. The compressive force is held until the PRM stops (event known as 'Still point'). The compression will be held until the practitioner feels PRM gradual return; the compression will be slowly diminished, and then, the practitioner remove the hands from the occipital bone, laying the participant's head on the table.~The CV4 technique will be performed by an osteopath D.O. - member of the Brazilian Register of Osteopaths.
Study NCT02111382 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CV4 (4th ventricle technique) manual therapy sham technique
Description: The participant will be in supine position and the practitioner will be seated behind the participant's head. The practitioner places the fingers (2nd to 5th) under the occipital bone, touching only the squama occipitalis. The practitioner will hold this position for 5 minutes, and after this period the participant's head will be placed on the table.~The CV4 sham will be performed by a registered physiotherapist.
Study NCT04390074 — intervention group
Intervention type: OTHER
Intervention: COVID-19 and Intensive Care
Description: No intervention, observational.
Study NCT03154931 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CBT-SG
Description: To support the group.
Study NCT03154931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CFT-G
Description: Teach compassionate skills.
Study NCT02770053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foraminal enlargement
Description: After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
Study NCT02770053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Foraminal enlargement
Description: After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
Study NCT04303117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NHS-IL12
Description: An initial dose of 16.8 mcg/kg administered subcutaneously every 4 weeks and at an MTD dose with M7824 on day 1 of a 28-day cycle.
Study NCT04303117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1200 mg administered IV every two weeks while on NHS-IL12.
Study NCT01206946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: A single course of betamethasone (two doses of 12 mg/dose given at 24 hourly intervals)
Study NCT01206946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Two doses of 2ml of normal saline given at 24 hourly intervals
Study NCT00254488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium (LI)
Description: The starting LI dose will be 150 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma LI level ranges between 0.40 and 0.99 mEq/L (target 0.80 to 0.99 mEq/L).
Study NCT00254488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex (DV)
Description: Dosage of DV will be 250 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma DV level ranges between 40 and 99 mcg/mL (target 80 to 99 mcg/ml).
Study NCT04310735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verbal smoking expectancy manipulation
Description: Instructions regarding whether or not participants will have an opportunity to smoke during the experimental session.
Study NCT04398888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Banxie Xiexin Decoction (BXD)
Description: A modified Banxie Xiexin Decoction based on Chinese medicine syndrome differentiation.